Trans-catheter arterial chemoembolization plus Sorafenib, an unsuccessful therapy in the treatment of hepatocellular carcinoma?: A systematic review and meta-analysis

BACKGROUND: Trans-catheter arterial chemoembolization (TACE) plus Sorafenib is recommended as one of the primary means for treating hepatocellular carcinoma (HCC). This updated meta-analysis focuses on identifying the efficacy and safety of TACE plus Sorafenib versus TACE, which remains controversia...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tao, Huang, Weisen, Dong, Haorong, Chen, Yijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373552/
https://www.ncbi.nlm.nih.gov/pubmed/32702836
http://dx.doi.org/10.1097/MD.0000000000020962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373552/
https://www.ncbi.nlm.nih.gov/pubmed/32702836
http://dx.doi.org/10.1097/MD.0000000000020962

Ejemplares similares